Maricann Group, Inc. Stock (OTC: MRRCF) (CSE: MARI) - Investor Dashboard

Summary

Financials (03/31/18)

Capital Structure (08/10/18)

Company Brief

Maricann Group Inc., was founded in 2013 and is based in a well-established agricultural region in southwestern Ontario, Canada. In March of 2014 Maricann earned a Health Canada license to cultivate plants and in December earned a license from Health Canada to sell dried flower.

The company sold $1.97mm dried cannabis in 2015. In 2016, the company purchased 97.5 contiguous acres while earning a license to sell cannabis extracts. Maricann is partnered with Evolab, its Colorado-based extraction technology partner, to access its leading technology and processes.

 Maricann grows all-natural plants in its energy-efficient greenhouse, while maintaining secure and consistent supply, as it has focused on eight profitable and proven strains and is aiming for production costs of $1.34 per gram.

Maricann is currently expanding domestic and international capacity and distribution channels. In Germany, Maricann has commenced a retrofit of a 500,000 square-foot cultivation facility and is preparing to cultivate all-natural plants in a portion of the facility in Dresden. The company raised $40mm by way of private placement in 2018.

Expanding in Mature Markets

Maricann’s GMP-compliant clean-room cultivation facility in Dresden, Germany leaves it very well positioned for growth in a large market.

German Parliamentarians voted unanimously in January 2017 in favor of the new “Cannabis as Medicine” law, which will create a large market with insurance coverage and pharmacy distribution and will allow Maricann to expand throughout the European Union.

Highlights

• Licensed by Health Canada since 2014
• Focus on both medical and lifestyle cannabis
• Management team experienced in cultivation, pharmaceuticals, distribution, and healthcare
• Selling dried flower, oils, resin and clones
• Raised $40mm in 2018
• Forecasting strong production and sales growth following facilities expansion
• Three core brands: Kiwi, Rare Darkness, and High Tide

Growth Strategy

• Expanding Langton, Ontario greenhouse in three phases
• 820,000 square feet of cleanroom cultivation available once the Ebersbach facility in Germany is completed
• Virtual pharmacies in physical locations and seminars and education offered by Synergy Health Clinics
• Acquired biotech company NanoLeaf Technologies and Swiss company Haxxon AG
• Memorandum of understanding with British Columbia to supply 3,621,900 grams of non-medicinal cannabis
• 550,000-gram supply agreement with Manitoba
• Allocating approximately 3,375 kilograms of product for the Alberta market

Differentiators

• Focus on energy efficiency using glass greenhouse
• Intending to apply for a German cultivation license
• Focus on eight proven and profitable strains
• Canada-wide pharmacy partnership
• Joint venture with Evolab, a leading Colorado extraction technology partner
• Exclusive provider of medical cannabis to Lovell Drugs
• Supply agreements with Alberta Gaming, Liquor and Cannabis Commission and the Ontario Cannabis Store
• License to manufacture medical cannabis in Malta